• Home
  • About Us
    • About Us
    • Subscribe
    • Privacy Policy
  • Advertise
    • Advertise On IP Watch
    • Editorial Calendar
  • Videos
  • Links
  • Help

Intellectual Property Watch

Original news and analysis on international IP policy

  • Copyright
  • Patents
  • Trademarks
  • Opinions
  • People News
  • Venues
    • Bilateral/Regional Negotiations
    • ITU/ICANN
    • United Nations – other
    • WHO
    • WIPO
    • WTO/TRIPS
    • Africa
    • Asia/Pacific
    • Europe
    • Latin America/Caribbean
    • North America
  • Themes
    • Access to Knowledge/ Open Innovation & Science
    • Food Security/ Agriculture/ Genetic Resources
    • Finance
    • Health & IP
    • Human Rights
    • Internet Governance/ Digital Economy/ Cyberspace
    • Lobbying
    • Technical Cooperation/ Technology Transfer
  • Health Policy Watch

GSK Eases IP Rights For Poorest Countries, Considers Patent Pooling For Cancer

31/03/2016 by Catherine Saez, Intellectual Property Watch 2 Comments

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

As the United Nations Secretary General’s High-Level Panel on Access to Medicines initiative continues its work, the GlaxoSmithKline company today announced steps to further help bring innovative medicines to poor countries.

The global medicines manufacturer said it wishes to widen access to its innovative new medicines around the world. The company, which already set tiered pricing, data-sharing, and “innovative partnerships,” said it recognises that improved access “requires a flexible and multi-faceted approach to intellectual property (IP) protection,” according to a press release.

GSK is evolving its graduated approach to filing and enforcing patents so that IP protection reflects a country’s economic maturity, said the release.

“For Least Developed Countries (LDCs) and Low Income Countries (LICs), GSK will not file patents for its medicines, so as to give clarity and confidence to generic companies seeking to manufacture and supply generic versions of GSK medicines in those countries.”

“For Lower Middle Income Countries (LMICs) generally, GSK will file for patents but will seek to offer and agree licences to allow supplies of generic versions of its medicines for 10 years.” A small royalty on sales is envisaged for those countries, said the release.

For the rest of the countries, GSK “will continue to seek full patent protection.”

Furthermore, GSK said it intends to commit its future portfolio of cancer treatments to patent pooling and ” will explore the concept with the Medicines Patent Pool (MPP) to help address the increasing burden of cancer in developing countries.” “GSK would be the first company to take this step.”

“Changes to patents and IP systems will not solve the multi-faceted challenges of improving healthcare in developing countries,” it said. “In cancer for example, improving outcomes in developing countries requires better funding, improved screening and diagnosis, more cancer doctors and better hospital services as well as access to treatments.”

Public health advocates Knowledge Ecology International applauded the GSK decisions and said Sir Andrew Witty (CEO of GSK) “has shown exceptional leadership.” In an announcement, KEI said, “The decision by GSK to license patents on cancer drugs to the Medicines Patent Pool (MPP) is welcome and impressive news.”

Sir Andrew Witty, CEO of GlaxoSmithKline

Sir Andrew Witty, CEO of GlaxoSmithKline

Witty, who recently announced he will be stepping down, is a member of the UN High-Level Panel. The panel is meeting this week behind closed doors on Long Island, New York to start drafting its report due in June.

“All of the MPP licenses apply to a limited number of countries, and do not address all of the important access challenges,” KEI said. “For this reason, it has been important that the MPP licenses have also allowed products manufactured under an MPP license to be exported to countries outside of the licensed territory, where there is no patent or where compulsory licenses have been issued.”

“We also expect the GSK licenses for cancer drugs to permit exports outside of the territory, where the exports are otherwise lawful in the importing country.”

“Other companies, such as Roche, Novartis, Bayer, Astellas, and BMS, with important oncology drugs should begin to engage on expanding access to their patented medicines, beyond just HIV and HCV drugs,” KEI urged.

 

Image Credits: GlaxoSmithKline

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

Related

Catherine Saez may be reached at csaez@ip-watch.ch.

Creative Commons License"GSK Eases IP Rights For Poorest Countries, Considers Patent Pooling For Cancer" by Intellectual Property Watch is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Filed Under: IP Policies, Language, Themes, Venues, Development, English, Finance, Health & IP, Innovation/ R&D, Patents/Designs/Trade Secrets, Technical Cooperation/ Technology Transfer, WHO

Trackbacks

  1. EUIPO y sus Sospechosa Relación con la EPO | Techrights says:
    03/04/2016 at 7:42 pm

    […] criminal que afectaba a los pacientes de cancer. Como resulta basado en nuevos reportajes (e.g. [1, 2]), GSK considera no mantener un monopolio (usando patentes) en ciertos tratamientos contra el […]

    Reply
  2. MPP Amends HIV Licensing Agreement To Cover More Countries says:
    25/04/2016 at 1:01 pm

    […] The expansion “comes on the heels of ViiV Healthcare majority shareholder GlaxoSmithKline’s March 31 announcement of its new approach to managing intellectual property based on country economic maturity, and its intention of broadening licensing for countries that fall under the lower middle-income category as defined by the World Bank” (IPW, Public Health, 31 March 2016). […]

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • Vimeo
My Tweets

IPW News Briefs

Saudis Seek Alternative Energy Partners Through WIPO Green Program

Chinese IP Officials Complete Study Of UK, European IP Law

Perspectives on the US

In US, No Remedies For Growing IP Infringements

US IP Law – Big Developments On The Horizon In 2019

More perspectives on the US...

Supported Series: Civil Society And TRIPS Flexibilities

Civil Society And TRIPS Flexibilities Series – Translations Now Available

The Myth Of IP Incentives For All Nations – Q&A With Carlos Correa

Read the TRIPS flexibilities series...

Paid Content

Interview With Peter Vanderheyden, CEO Of Article One Partners

More paid content...

IP Delegates in Geneva

  • IP Delegates in Geneva
  • Guide to Geneva-based Public Health and IP Organisations

All Story Categories

Other Languages

  • Français
  • Español
  • 中文
  • اللغة العربية

Archives

  • Archives
  • Monthly Reporter

Staff Access

  • Writers

Sign up for free news alerts

This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy

Copyright © 2022 · Global Policy Reporting

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.